WO2008037047A1 - Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance - Google Patents
Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance Download PDFInfo
- Publication number
- WO2008037047A1 WO2008037047A1 PCT/CA2006/001566 CA2006001566W WO2008037047A1 WO 2008037047 A1 WO2008037047 A1 WO 2008037047A1 CA 2006001566 W CA2006001566 W CA 2006001566W WO 2008037047 A1 WO2008037047 A1 WO 2008037047A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- muscle
- increasing
- phosphate
- creatinol
- composition
- Prior art date
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 31
- 230000001965 increasing effect Effects 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 15
- 230000037147 athletic performance Effects 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims description 23
- 230000003247 decreasing effect Effects 0.000 title abstract description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 68
- FOIPWTMKYXWFGC-UHFFFAOYSA-N creatinolfosfate Chemical compound NC(=N)N(C)CCOP(O)(O)=O FOIPWTMKYXWFGC-UHFFFAOYSA-N 0.000 claims abstract description 49
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 43
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 33
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 33
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 26
- 229960003624 creatine Drugs 0.000 description 13
- 239000006046 creatine Substances 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 239000007894 caplet Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 230000002608 insulinlike Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 229950007002 phosphocreatine Drugs 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000003293 cardioprotective effect Effects 0.000 description 2
- 229960004826 creatine monohydrate Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- QVJPPFAOCXDDPW-UHFFFAOYSA-N 5-[chloro(difluoro)methyl]-1,2-oxazole Chemical compound FC(F)(Cl)C1=CC=NO1 QVJPPFAOCXDDPW-UHFFFAOYSA-N 0.000 description 1
- 102100028292 Aladin Human genes 0.000 description 1
- 101710065039 Aladin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- -1 ester derivative of creatine Chemical class 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000019464 regulation of glucose import Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to the composition of a dietary supplement directed towards increasing lean muscle mass, and improving athletic performance. Through oral administration of the composition, a method for producing the same is also provided.
- a composition and method for increasing muscle strength, increasing lean muscle mass, and improving athletic performance.
- a composition and method comprising at least a combination of Creatinol-O-Phosphate and Alpha Lipoic Acid directed towards increasing muscle strength, increasing lean muscle mass, and improving athletic performance.
- Insulin is involved in the carbohydrate-induced uptake of glucose by cells. The release of glucose from cells is also concomitantly inhibited by insulin and its storage as glycogen and triglycerides is promoted (Khan AH, Pessin JE. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia. 2002 Nov;45(l l): 1475-83). Additionally, insulin has also been shown to stimulate the uptake of amino acids by muscle cells and stimulate protein synthesis (Biolo G, Declan Fleming RY, Wolfe RR. Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle. J Clin Invest.
- Alpha Lipoic Acid has been shown to have insulin-like activity in terms of glucose metabolism (Streeper RS, Henriksen EJ, Jacob S, Hokama JY, Fogt DL, Tritschler HJ. Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle. Am J Physiol.
- Creatine use has been thoroughly studied and it is well-establish as a beneficial dietary supplement for replenishing energy stores in working muscle cells (Greenhaff PL, Bodin K, Soderlund K, Hultman E. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol. 1994 May;266(5 Pt l):E725-30), thereby increasing strength, reducing fatigue resulting from high-intensity exercise (Greenhaff PL, Casey A, Short AH, Harris R, Soderlund K, Hultman E. Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin Sci (Lond).
- the present invention is directed to increasing muscle strength, increasing lean muscle mass, and improving athletic performance.
- the present invention comprises at least Creatinol-O-Phosphate or derivatives thereof and Alpha Lipoic Acid or derivatives thereof. Creatinol O-Phosphate
- Creatinol O-Phosphate also known by the synonyms, (N-methyl-N-(beta-hydroxyethyl) guanidine O-phosphate, COP, and (CAS: 6903-79-3), is a phosphoric ester derivative of creatine.
- Creatinol O-Phosphate has been shown to be well tolerated and without side effects (Melloni GF, Minoja GM, Lureti GF, Merlo L, Pamparana F, Brusoni B. Acute clinical tolerance of creatinol O-phosphate. Arzneiffenbachforschung. 1979, 29(9a): 1447-9).
- Creatinol-O-Phosphate Early studies of Creatinol-O-Phosphate explored its use as a treatment for heart lesions and also its ability to restore reduced cardiac contractile function. As a result of these early studies, Creatinol-O- Phosphate has been successfully used to improve cardiac parameters in patients with inadequate coronary blood flow (Barlattani M, Guglielmi G, Mammarella A. Creatinol O-phosphate therapy in patients with inadequate coronary circulation. Double-blind clinical trial. Arzneistoffforschung. 1979;29(9a): 1483-5).
- Creatinol-O-Phosphate hypothesized that the cardioprotective effect of Creatinol-O-Phosphate was due to action on anaerobic glycolysis (Godfraind T, Saleh MM. Action of creatinol-O- phosphate on the contractility changes evoked by hypoxia and ischemia in rat isolated heart. Arzneistoffforschung. 1984;34(9):968-72).
- Creatinol-O-Phosphate is an effect in the electrophysiological properties of the cell membrane as shown by other investigators (Botti G, Bonatti V. Preliminary report on electrophysiological effectiveness of creatinol O-phosphate (COP) in human subjects. Arzneistoffaria. 1979;29(9a): 1491 -4).
- Creatinol-O-Phosphate in addition to its cardio-protective effects, has been has also been shown to improve muscle development and increase the capacity of a muscle to perform physical activity.
- hand-grip strength was improved by Creatinol-O-Phosphate administration and while remaining unaffected in a placebo group (Nicaise J. Creatinol O-phosphate (COP) and muscular performance: a controlled clinical trial. Curr Ther Res Clin Exp. 1975, 17(6):531-4).
- Creatinol-O- Phosphate improved muscular performance as compared to controls (Cavalieri U, Quadri A, Ghirardi F.
- Creatinol-O-Phosphate functions in a similar to that of Creatine, which is well known is in art, in addition to possibly possessing unique properties. Creatinol-O-Phosphate administration has been found to increase urine levels of creatinine (Melloni GF, Minoja GM, Lureti GF, Merlo L, Pamparana F, Brusoni B. Acute clinical tolerance of creatinol O-phosphate. Arzneiffenbachaba.
- Creatinol-O-Phosphate may therefore enhance athletic performance and muscle growth in a manner similar to that of creatine, aiding in the rapid rephosphorylation of ATP to provide energy to a given muscle (Greenhaff PL, Bodin K, Soderlund K, Hultman E. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol.
- a dietary supplement includes Creatinol-O-Phosphate or derivatives thereof.
- a serving of the dietary supplement may include from about 0.250 g to about 5.0 g of Creatinol-O-Phosphate or derivatives thereof.
- the preferred dosage, in a serving of said dietary supplement comprises about 1.0 g of Creatinol-O-Phosphate or derivatives thereof.
- Alpha Lipoic Acid is an enzyme found in the cellular energy-producing structures, the mitochondria. Moreover, ALA works in synergy with vitamins C and E as an antioxidant in both the water- and fat- soluble environments. Negative age-related changes in mitochondrial function, accumulated oxidative damage and metabolic rate were all improved (Hagen TM, Ingersoll RT, Lykkesfeldt J, Liu J, Wehr CM, Vinarsky V, Bartholomew JC, Ames AB. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J.
- Alpha Lipoic Acid may enhance the uptake and retention of supplemental Creatinol-O-Phosphate or derivatives thereof in a manner similar to that of the enhanced Creatine retention induced by Alpha Lipoic Acid with respect muscle cells (Burke DG, chilibeck PD, Parise G, Tarnopolsky MA, Candow DG.
- a dietary supplement may include Alpha Lipoic Acid or derivatives thereof.
- a serving of the dietary supplement may include from about 0.005 g to about 0.1 g of Alpha Lipoic
- the preferred dosage of a serving of the dietary supplement comprises about 0.010 g of Alpha Lipoic Acid or derivatives thereof.
- the dietary supplement comprises at least a combination of Creatinol-O-Phosphate or derivatives thereof and Alpha Lipoic Acid or derivatives thereof.
- the dietary supplement may be consumed in any form.
- the dosage form of the diet supplement may be provided as, e.g., a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a tablet, a caplet, or as a dietary gel.
- the preferred dosage form of the present invention is as a caplet or tablet.
- the dosage form of said dietary supplement may be provided in accordance with customary processing techniques for dietary supplements in any of the forms mentioned above.
- the dietary supplement set forth in the example embodiments herein may contain any appropriate number and type of excipients, as is well-known in the art.
- the present dietary supplement or those similarly envisioned by one of ordinary skill in the art may be utilized in compositions and methods for increasing lean muscle mass,, increasing muscle strength and improving athletic performance.
- the dietary supplement of the present invention is consumed by an individual in accordance with the following method:
- a serving of said dietary supplement may be administered by means of consumption in conjunction with a liquid medium at least one (1) time daily wherein each serving is comprised of at least one (1) caplet or tablet.
- Said dietary supplement may be consumed immediately post-workout, pre-workout, or in the morning upon waking on non-workout days. In this manner, the dietary supplement may increase lean muscle mass, increase muscle strength and improve athletic performance.
- Example 1 illustrates the practice of the present invention in one of its embodiments, the example should not construed as limiting the scope of the invention. Other embodiments will be apparent to one of ordinary skill in the art from consideration of the specifications and example. Examples Example 1
- the ingredients of the dietary supplement may be consumed with 8 ounces of water.
- the composition of the dietary supplement includes Creatinol-O- Phosphate (1.0 g) and Alpha Lipoic Acid (0.010 g).
- the dietary supplement may be consumed at least one (1) time daily wherein said serving isconsumed immediately following exercise.
- the ingredients of the dietary supplement may be consumed with 8 ounces of water.
- the composition of the dietary supplement includes Creatinol-O- Phosphate (1.0 g) and Alpha Lipoic Acid (0.010 g).
- the dietary supplement may be consumed at least one (1) time daily wherein said serving is consumed immediately following exercise.
- the ingredients of the dietary supplement may be consumed with 8 ounces of water.
- the composition of the dietary supplement includes Creatinol-O- Phosphate (1.0 g) and Alpha Lipoic Acid (0.010 g).
- the dietary supplement may be at least one (1) time daily wherein said serving is consumed prior to exercise.
- the ingredients of the dietary supplement may be consumed with 8 ounces of water.
- the composition of the dietary supplement includes Creatinol-O- Phosphate (1.0 g) and Alpha Lipoic Acid (0.010 g).
- the dietary supplement may be at least one (1) time daily wherein said serving is consumed prior to exercise.
- the ingredients of the dietary supplement may be consumed with 8 ounces of water.
- the composition of the dietary supplement includes Creatinol-O- Phosphate (1 g) and Alpha Lipoic Acid (0.010 g).
- the dietary supplement may be consumed at least one (1) time daily wherein said serving is consumed upon waking in the morning.
- the ingredients of the dietary supplement may be consumed with 8 ounces of water.
- the composition of the dietary supplement includes Creatinol-O- Phosphate (1.0 g) and Alpha Lipoic Acid (0.010 g).
- the dietary supplement may be consumed at least one (1) time daily wherein said serving is consumed upon waking in the morning.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A dietary supplement and method directed at increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance. The dietary supplement comprises at least Creatinol-O-Phosphate or derivatives thereof and Alpha Lipoic Acid or derivatives thereof.
Description
COMPOSITION AND METHOD FOR INCREASING LEAN MUSCLE MASS,
DECREASING MUSCLE LOSS, INCREASING MUSCLE STRENGTH AND
IMPROVING ATHLETIC PERFORMANCE
Field of the Invention The present invention relates to the composition of a dietary supplement directed towards increasing lean muscle mass, and improving athletic performance. Through oral administration of the composition, a method for producing the same is also provided.
Summary of the Invention
The foregoing needs and other needs and objectives that will become apparent for the following description are achieved in the present invention which comprises a dietary supplement and method for increasing lean muscle mass, increasing muscle strength and improving athletic performance A preferred embodiment of the present invention, a composition and method is provided for increasing muscle strength, increasing lean muscle mass, and improving athletic performance. According to an embodiment of the present invention there is provided a composition and method comprising at least a combination of Creatinol-O-Phosphate and Alpha Lipoic Acid directed towards increasing muscle strength, increasing lean muscle mass, and improving athletic performance.
Background of the Invention Insulin is involved in the carbohydrate-induced uptake of glucose by cells. The release of glucose from cells is also concomitantly inhibited by insulin and its storage as glycogen and triglycerides is promoted (Khan AH, Pessin JE. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia. 2002 Nov;45(l l): 1475-83). Additionally, insulin has also been shown to stimulate the uptake of amino acids by muscle cells and stimulate protein synthesis (Biolo G, Declan Fleming RY, Wolfe RR. Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in
human skeletal muscle. J Clin Invest. 1995 Feb;95(2):811-9), particularly following exercise (Biolo G, Williams BD, Fleming RY, Wolfe RR. Insulin action on muscle protein kinetics and amino acid transport during recovery after resistance exercise. Diabetes. 1999 May;48(5):949- 57) which is required for increasing muscle mass and associated muscle function, i.e. strength. Alpha Lipoic Acid has been shown to have insulin-like activity in terms of glucose metabolism (Streeper RS, Henriksen EJ, Jacob S, Hokama JY, Fogt DL, Tritschler HJ. Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle. Am J Physiol. 1997 Jul;273(l Pt 1):E185-91; Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schutte K, Kerum G, Malessa R. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999 Aug;22(8): 1296-301). Likely due to this insulin-like activity, the combination of Alpha Lipoic Acid and Creatine, via supplementation has been shown to result in markedly improved uptake and retention of Creatine by skeletal muscle cells (Burke DG, Chilibeck PD, Parise G, Tarnopolsky MA, Candow DG. Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration. Int J Sport Nutr Exerc Metab. 2003 Sep;13(3):294-302).
Creatine use has been thoroughly studied and it is well-establish as a beneficial dietary supplement for replenishing energy stores in working muscle cells (Greenhaff PL, Bodin K, Soderlund K, Hultman E. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol. 1994 May;266(5 Pt l):E725-30), thereby increasing strength, reducing fatigue resulting from high-intensity exercise (Greenhaff PL, Casey A, Short AH, Harris R, Soderlund K, Hultman E. Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin Sci (Lond). 1993 May;84(5):565-71) as well as increasing muscle growth (Volek JS, Duncan ND, Mazzetti SA, Staron RS, Putukian M, Gomez AL, Pearson DR, Fink WJ, Kraemer WJ. Performance and
muscle fiber adaptations to creatine supplementation and heavy resistance training. Med Sci Sports Exerc. 1999 Aug;31(8): 1147-56).
Detailed Description of the Invention
In the following description, for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the present invention. It will be apparent, however, to one of ordinary skill in the art that the present invention may be practiced without these specific details.
While not wishing to be bound by theory, it is understood by the inventors that the beneficial activity of supplemental Creatinol-O-Phosphate, ,is improved through the combination of at least Creatinol-O-Phosphate and Alpha Lipoic Acid in a single dietary supplement wherein an increase in the uptake and retention of Creatinol-O-Phosphate results from the insulin-like activity of Alpha Lipoic Acid.
The present invention, according to various embodiments thereof, is directed to increasing muscle strength, increasing lean muscle mass, and improving athletic performance. The present invention comprises at least Creatinol-O-Phosphate or derivatives thereof and Alpha Lipoic Acid or derivatives thereof. Creatinol O-Phosphate
Creatinol O-Phosphate, also known by the synonyms, (N-methyl-N-(beta-hydroxyethyl) guanidine O-phosphate, COP, and (CAS: 6903-79-3), is a phosphoric ester derivative of creatine. As a supplement, Creatinol O-Phosphate has been shown to be well tolerated and without side effects (Melloni GF, Minoja GM, Lureti GF, Merlo L, Pamparana F, Brusoni B. Acute clinical tolerance of creatinol O-phosphate. Arzneimittelforschung. 1979, 29(9a): 1447-9). Early studies of Creatinol-O-Phosphate explored its use as a treatment for heart lesions and also its ability to restore reduced cardiac contractile function. As a result of these early studies, Creatinol-O- Phosphate has been successfully used to improve cardiac parameters in patients with inadequate coronary blood flow (Barlattani M, Guglielmi G, Mammarella A. Creatinol O-phosphate therapy
in patients with inadequate coronary circulation. Double-blind clinical trial. Arzneimittelforschung. 1979;29(9a): 1483-5). Additionally, early investigators of the properties of Creatinol-O-Phosphate hypothesized that the cardioprotective effect of Creatinol-O-Phosphate was due to action on anaerobic glycolysis (Godfraind T, Saleh MM. Action of creatinol-O- phosphate on the contractility changes evoked by hypoxia and ischemia in rat isolated heart. Arzneimittelforschung. 1984;34(9):968-72). Furthermore, an additional or alternative possible mechanism hypothesized in regard to Creatinol-O-Phosphate is an effect in the electrophysiological properties of the cell membrane as shown by other investigators (Botti G, Bonatti V. Preliminary report on electrophysiological effectiveness of creatinol O-phosphate (COP) in human subjects. Arzneimittelforschung. 1979;29(9a): 1491 -4).
Creatinol-O-Phosphate, in addition to its cardio-protective effects, has been has also been shown to improve muscle development and increase the capacity of a muscle to perform physical activity. In one study, hand-grip strength was improved by Creatinol-O-Phosphate administration and while remaining unaffected in a placebo group (Nicaise J. Creatinol O-phosphate (COP) and muscular performance: a controlled clinical trial. Curr Ther Res Clin Exp. 1975, 17(6):531-4). Moreover, in another study conducted in elderly subjects, it was found that Creatinol-O- Phosphate improved muscular performance as compared to controls (Cavalieri U, Quadri A, Ghirardi F. Effects of creatinol o-phosphate on the muscle function of elderly people. The Therapeutic Clinic. 1974, 69: 215-223). Creatinol-O-Phosphate functions in a similar to that of Creatine, which is well known is in art, in addition to possibly possessing unique properties. Creatinol-O-Phosphate administration has been found to increase urine levels of creatinine (Melloni GF, Minoja GM, Lureti GF, Merlo L, Pamparana F, Brusoni B. Acute clinical tolerance of creatinol O-phosphate. Arzneimittelforschung. 1979, 29(9a): 1447-9), the end metabolite and degradation product of creatine and phosphocreatine, which diffuses out of cells for later excretion by the kidneys. This metabolism to Creatinol-O-Phosphate may be due to phosphodiesterases contained within the body. Creatinol-O-Phosphate may therefore enhance athletic performance and muscle growth in
a manner similar to that of creatine, aiding in the rapid rephosphorylation of ATP to provide energy to a given muscle (Greenhaff PL, Bodin K, Soderlund K, Hultman E. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol. 1994, 266(5 Pt l):E725-30). In various embodiments of the present invention which are set forth in greater detail below in the examples below, a dietary supplement includes Creatinol-O-Phosphate or derivatives thereof. A serving of the dietary supplement may include from about 0.250 g to about 5.0 g of Creatinol-O-Phosphate or derivatives thereof. The preferred dosage, in a serving of said dietary supplement, comprises about 1.0 g of Creatinol-O-Phosphate or derivatives thereof.
Alpha Lipoic acid
Alpha Lipoic Acid (ALA) is an enzyme found in the cellular energy-producing structures, the mitochondria. Moreover, ALA works in synergy with vitamins C and E as an antioxidant in both the water- and fat- soluble environments. Negative age-related changes in mitochondrial function, accumulated oxidative damage and metabolic rate were all improved (Hagen TM, Ingersoll RT, Lykkesfeldt J, Liu J, Wehr CM, Vinarsky V, Bartholomew JC, Ames AB. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J. 1999 Feb;13(2):411-8) in rats supplemented with ALA, thereby indicating its protective effects in these parameters. As such, the antioxidant activity of ALA is likely involved in the prevention of cell death due to an improvement in oxidative stress (Arivazhagan P, Juliet P, Panneerselvam C. Effect of dl-alpha-lipoic acid on the status of lipid peroxidation and antioxidants in aged rats. Pharmacol Res. 2000 Mar;41(3):299-303). Furthermore, ALA has been linked to a beneficial increase in high-density lipoproteins (Wollin SD, Wang Y, Kubow S, Jones PJ. Effects of a medium chain triglyceride oil mixture and alpha-lipoic acid diet on body composition, antioxidant status, and plasma lipid levels in the Golden Syrian hamster. J Nutr Biochem. 2004 Jul;15(7):402-10) possibly due to its known effects as an antioxidant.
Further to its insulin-like activity, Alpha Lipoic Acid may enhance the uptake and retention of supplemental Creatinol-O-Phosphate or derivatives thereof in a manner similar to that of the enhanced Creatine retention induced by Alpha Lipoic Acid with respect muscle cells (Burke DG, Chilibeck PD, Parise G, Tarnopolsky MA, Candow DG. Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration. Int J Sport Nutr Exerc Metab. 2003 Sep;13(3):294-302) thereby enhancing the effects of Creatinol-O-Phosphate or derivatives thereof through an increase in retention.
In an embodiment of the present invention, which is set forth in greater detail in the examples below, a dietary supplement may include Alpha Lipoic Acid or derivatives thereof. A serving of the dietary supplement may include from about 0.005 g to about 0.1 g of Alpha Lipoic
Acid or derivatives thereof. The preferred dosage of a serving of the dietary supplement comprises about 0.010 g of Alpha Lipoic Acid or derivatives thereof.
In a preferred embodiment of the present invention, the dietary supplement comprises at least a combination of Creatinol-O-Phosphate or derivatives thereof and Alpha Lipoic Acid or derivatives thereof.
It is understood by the inventors that advantageously, the combination of ALA and Creatinol-O-Phosphate subsequent co-administration in the form of a dietary supplement will enhance the retention of Creatinol-O-Phosphate in the body.
According to various embodiments of the present invention, the dietary supplement may be consumed in any form. For instance, the dosage form of the diet supplement may be provided as, e.g., a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a tablet, a caplet, or as a dietary gel. The preferred dosage form of the present invention is as a caplet or tablet.
Furthermore, the dosage form of said dietary supplement may be provided in accordance with customary processing techniques for dietary supplements in any of the forms mentioned above. Additionally, the dietary supplement set forth in the example embodiments herein may contain any appropriate number and type of excipients, as is well-known in the art.
The present dietary supplement or those similarly envisioned by one of ordinary skill in the art, may be utilized in compositions and methods for increasing lean muscle mass,, increasing muscle strength and improving athletic performance.
Preferably, the dietary supplement of the present invention is consumed by an individual in accordance with the following method: As a dietary supplement, a serving of said dietary supplement may be administered by means of consumption in conjunction with a liquid medium at least one (1) time daily wherein each serving is comprised of at least one (1) caplet or tablet.
Said dietary supplement may be consumed immediately post-workout, pre-workout, or in the morning upon waking on non-workout days. In this manner, the dietary supplement may increase lean muscle mass, increase muscle strength and improve athletic performance.
Although the following example illustrates the practice of the present invention in one of its embodiments, the example should not construed as limiting the scope of the invention. Other embodiments will be apparent to one of ordinary skill in the art from consideration of the specifications and example. Examples Example 1
The ingredients of the dietary supplement, supplied in caplet form, may be consumed with 8 ounces of water. The composition of the dietary supplement includes Creatinol-O- Phosphate (1.0 g) and Alpha Lipoic Acid (0.010 g). The dietary supplement may be consumed at least one (1) time daily wherein said serving isconsumed immediately following exercise. Example 2
The ingredients of the dietary supplement, supplied in tablet form, may be consumed with 8 ounces of water. The composition of the dietary supplement includes Creatinol-O- Phosphate (1.0 g) and Alpha Lipoic Acid (0.010 g). The dietary supplement may be consumed at least one (1) time daily wherein said serving is consumed immediately following exercise.
Example 3
The ingredients of the dietary supplement, supplied in caplet form, may be consumed with 8 ounces of water. The composition of the dietary supplement includes Creatinol-O- Phosphate (1.0 g) and Alpha Lipoic Acid (0.010 g). The dietary supplement may be at least one (1) time daily wherein said serving is consumed prior to exercise. Example 4
The ingredients of the dietary supplement, supplied in tablet form, may be consumed with 8 ounces of water. The composition of the dietary supplement includes Creatinol-O- Phosphate (1.0 g) and Alpha Lipoic Acid (0.010 g). The dietary supplement may be at least one (1) time daily wherein said serving is consumed prior to exercise. Example 5
The ingredients of the dietary supplement, supplied in tablet form, may be consumed with 8 ounces of water. The composition of the dietary supplement includes Creatinol-O- Phosphate (1 g) and Alpha Lipoic Acid (0.010 g). The dietary supplement may be consumed at least one (1) time daily wherein said serving is consumed upon waking in the morning. Example 6
The ingredients of the dietary supplement, supplied in caplet form, may be consumed with 8 ounces of water. The composition of the dietary supplement includes Creatinol-O- Phosphate (1.0 g) and Alpha Lipoic Acid (0.010 g). The dietary supplement may be consumed at least one (1) time daily wherein said serving is consumed upon waking in the morning. Extensions and Alternatives
In the foregoing specification, the invention has been described with specific embodiments thereof however, it will be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the invention.
Claims
1. A dietary supplement comprising at least Creatinol-O-Phosphate or derivatives thereof and Alpha Lipoic Acid or derivatives thereof.
2. A method of increasing lean muscle mass in an individual comprising at least the step of consuming the composition of claim 1.
3. A method of increasing muscle strength in an individual comprising at least the step of consuming the composition of claim 1.
4. A method of improving athletic performance in an individual comprising at least the step of consuming the composition of claim 1.
5. A composition comprising: about 1.0 g of Creatinol-O-Phosphate or derivative thereof; about 0.01Og of Alpha Lipoic Acid or derivative thereof.
6. A method of increasing lean muscle mass in an individual comprising at least the step of consuming the composition of claim 5.
7. A method of increasing muscle strength in an individual comprising at least the step of consuming the composition of claim 5.
8. A method of improving athletic performance in an individual comprising at least the step of consuming the composition of claim 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2006/001566 WO2008037047A1 (en) | 2006-09-25 | 2006-09-25 | Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2006/001566 WO2008037047A1 (en) | 2006-09-25 | 2006-09-25 | Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008037047A1 true WO2008037047A1 (en) | 2008-04-03 |
Family
ID=39229656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA2006/001566 WO2008037047A1 (en) | 2006-09-25 | 2006-09-25 | Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008037047A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2276494A1 (en) * | 2008-04-09 | 2011-01-26 | John H. Owoc | Stable aqueous compositions comprising bioactive creatine species |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136339A (en) * | 1998-08-21 | 2000-10-24 | Gardiner; Paul T. | Food supplements and methods comprising lipoic acid and creatine |
| US20050192183A1 (en) * | 2004-03-01 | 2005-09-01 | Thomas Gastner | Use of guanidine compounds as physiological strengthening agents in the form of nutritional supplements, animal feed additives, in cosmetic preparations and as plant stimulants |
| WO2006034586A1 (en) * | 2004-09-29 | 2006-04-06 | Aplodan Formulations Ltd. | Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker |
-
2006
- 2006-09-25 WO PCT/CA2006/001566 patent/WO2008037047A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136339A (en) * | 1998-08-21 | 2000-10-24 | Gardiner; Paul T. | Food supplements and methods comprising lipoic acid and creatine |
| US20050192183A1 (en) * | 2004-03-01 | 2005-09-01 | Thomas Gastner | Use of guanidine compounds as physiological strengthening agents in the form of nutritional supplements, animal feed additives, in cosmetic preparations and as plant stimulants |
| WO2006034586A1 (en) * | 2004-09-29 | 2006-04-06 | Aplodan Formulations Ltd. | Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker |
Non-Patent Citations (1)
| Title |
|---|
| 2 March 2007 (2007-03-02), Retrieved from the Internet <URL:http://www.muscletech.com/PRODUCTS/APLODAN/index.shtml> * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2276494A1 (en) * | 2008-04-09 | 2011-01-26 | John H. Owoc | Stable aqueous compositions comprising bioactive creatine species |
| EP2276494A4 (en) * | 2008-04-09 | 2011-10-19 | John H Owoc | Stable aqueous compositions comprising bioactive creatine species |
| US8372821B2 (en) * | 2008-04-09 | 2013-02-12 | Jack H. Owoc | Stable aqueous compositions comprising bioactive creatine species |
| US9114150B2 (en) | 2008-04-09 | 2015-08-25 | Jho Intellectual Property Holdings, Llc | Stable aqueous compositions comprising bioactive creatine species |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7790688B2 (en) | Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly | |
| US20080317886A1 (en) | Compositions for Preventing and Reducing Delayed Onset Muscle Soreness | |
| KR100545630B1 (en) | Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides | |
| EP0969744B1 (en) | Nutritional composition for improvements in cell energetics | |
| US20090142410A1 (en) | Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise | |
| AU5387199A (en) | Antioxidant composition comprising acetyl l-carnitine and alpha-lipoic acid | |
| US20200129463A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
| EP1087779A2 (en) | Compositions for increasing energy in vivo | |
| US20050282772A1 (en) | New dietary supplement composition for obesity and inflammation | |
| JP2019031504A (en) | Transmucosal delivery of tocotrienol | |
| EP1258243A1 (en) | Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy | |
| JP2006506361A (en) | Therapeutic combination of carnitine and antioxidant polyphenols | |
| US20160303176A1 (en) | Nutritional supplement | |
| WO2004112511A2 (en) | Supplement for restoring growth hormone levels | |
| WO2014116985A1 (en) | Composition for treatment of neurodegenerative disease | |
| WO2008037047A1 (en) | Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance | |
| US20080095865A1 (en) | Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance | |
| US8318954B2 (en) | Cleavable carnitine compound | |
| US20220339142A1 (en) | Administration of r-beta-hydroxybutyrate salt blend and related compounds in humans | |
| US20220362188A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
| EP3727359B1 (en) | Treatment of fibrosis with inositol | |
| US20230149329A1 (en) | C5 ketone compositions and related methods for therapeutic and performance supplementation | |
| EP1745789A1 (en) | Compositions comprising ribose for increasing energy in vivo | |
| US20120172450A1 (en) | Use of jasmonate for improving skeletal muscle function | |
| WO2022254185A1 (en) | Nutritional compositions for skeletal muscle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06790732 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06790732 Country of ref document: EP Kind code of ref document: A1 |